FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330761719> ?p ?o ?g. }

• W2330761719 endingPage "564" @default.
• W2330761719 startingPage "564.1" @default.
• W2330761719 abstract "<h3>Background</h3> Vasculopathy is a major pathophysiological problem in patients with systemic sclerosis (SSc) and the main cause for Raynaud phenomenon (RP), digital ulcerations (DU), pulmonary arterial hypertension (PAH). It is not known, how SSc patients are treated with vasoactive agents in daily practice. <h3>Objectives</h3> To determine, to which extent SSc patients are treated with vasoactive drugs. <h3>Methods</h3> Data of 3248 patients of the registry of German Network for Systemic Scleroderma were analyzed. <h3>Results</h3> Patients were treated with vasoactive drugs in 54.9% (1784) cases. Of these, 53% received calcium channel inhibitors (CCI), followed by 23.5% treated with intravenous Prostanoids (Iloprost, Prostavasin), 11.8% with beta-blockers, 11.3% with Pentoxifylline, 9.7% with Endothelin 1 receptor antagonists (ETRA), 4.6% with PDE5 inhibitors, 2.7% with topical vasodilative agents and 3.2% with others. Patients with RP received vasoactive therapy in 47,4%, with DU in 66,8% and with PAH in 71,6% of cases. Logistic regression analysis revealed, that patients who suffered from PAH were significantly more often treated with PDE5 inhibitors (odds ratio (OR) 7.2; p<0.0001) and ETRA (OR 6.9; p<0.0001) and those with digital ulcers with ETRA (OR 2.8; p<0.0001) and intravenous prostanoids (OR 1.7; p<0.0001). Patients were more frequently treated with β-blockers, when they had arterial hypertension (OR 4.2; p<0.0001) and were male (OR 1.9; p<0.0001). In addition 25,6% (830) patients were treated with ACE-inhibitors or AT1-receptor antagonists. They were often male and suffered from the diffuse form of SSc (p<0.001). Logistic regression analysis within this group clearly indicated that patients with hypertension (OR 4.9; p<0.0001) and renal insufficiency (OR 3.0; p<0.0001) were significantly more often treated with ACE inhibitors. When patients, registered after 2009, were compared to patients registered prior to 2004, it was found that after 2009 significantly more patients received ETRA (12% vs 5.5%; p<0.0001), beta-blockers (14.1% vs 7.6%; p<0.001), AT1R antagonists (12.5% vs 4.6%; p<0.0001), intravenous prostanoids (26.6% vs 18.2%; p<0.001) and ACE inhibitors (28.6% vs 23.1%; p<0.008). <h3>Conclusions</h3> These data clearly indicate that many SSc patients with RP, DU, and PAH do not yet receive sufficient vasoactive therapy. Furthermore, in recent years a marked change of treatment regimens can be observed. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4946" @default.
• W2330761719 created "2016-06-24" @default.
• W2330761719 creator A5000312441 @default.
• W2330761719 creator A5003196348 @default.
• W2330761719 creator A5004777519 @default.
• W2330761719 creator A5007615241 @default.
• W2330761719 creator A5008702824 @default.
• W2330761719 creator A5009019101 @default.
• W2330761719 creator A5024201364 @default.
• W2330761719 creator A5030332737 @default.
• W2330761719 creator A5035816121 @default.
• W2330761719 creator A5038984237 @default.
• W2330761719 creator A5040057210 @default.
• W2330761719 creator A5041627641 @default.
• W2330761719 creator A5044349612 @default.
• W2330761719 creator A5046636617 @default.
• W2330761719 creator A5048381898 @default.
• W2330761719 creator A5054306952 @default.
• W2330761719 creator A5065746861 @default.
• W2330761719 creator A5068745902 @default.
• W2330761719 creator A5069180045 @default.
• W2330761719 creator A5074076474 @default.
• W2330761719 creator A5078749744 @default.
• W2330761719 creator A5083044979 @default.
• W2330761719 creator A5083956139 @default.
• W2330761719 creator A5087211317 @default.
• W2330761719 creator A5090063962 @default.
• W2330761719 creator A5077491183 @default.
• W2330761719 date "2014-06-01" @default.
• W2330761719 modified "2023-10-01" @default.
• W2330761719 title "FRI0488 Analysis of REAL Life Vasoactive Therapy in over 3000 Patients with Systemic Sclerosis (SSC) Reveals Considerable Undertreatment and Significant Changes of Treatment Practice since 2004" @default.
• W2330761719 doi "https://doi.org/10.1136/annrheumdis-2014-eular.4946" @default.
• W2330761719 hasPublicationYear "2014" @default.
• W2330761719 type Work @default.
• W2330761719 sameAs 2330761719 @default.
• W2330761719 citedByCount "0" @default.
• W2330761719 crossrefType "journal-article" @default.
• W2330761719 hasAuthorship W2330761719A5000312441 @default.
• W2330761719 hasAuthorship W2330761719A5003196348 @default.
• W2330761719 hasAuthorship W2330761719A5004777519 @default.
• W2330761719 hasAuthorship W2330761719A5007615241 @default.
• W2330761719 hasAuthorship W2330761719A5008702824 @default.
• W2330761719 hasAuthorship W2330761719A5009019101 @default.
• W2330761719 hasAuthorship W2330761719A5024201364 @default.
• W2330761719 hasAuthorship W2330761719A5030332737 @default.
• W2330761719 hasAuthorship W2330761719A5035816121 @default.
• W2330761719 hasAuthorship W2330761719A5038984237 @default.
• W2330761719 hasAuthorship W2330761719A5040057210 @default.
• W2330761719 hasAuthorship W2330761719A5041627641 @default.
• W2330761719 hasAuthorship W2330761719A5044349612 @default.
• W2330761719 hasAuthorship W2330761719A5046636617 @default.
• W2330761719 hasAuthorship W2330761719A5048381898 @default.
• W2330761719 hasAuthorship W2330761719A5054306952 @default.
• W2330761719 hasAuthorship W2330761719A5065746861 @default.
• W2330761719 hasAuthorship W2330761719A5068745902 @default.
• W2330761719 hasAuthorship W2330761719A5069180045 @default.
• W2330761719 hasAuthorship W2330761719A5074076474 @default.
• W2330761719 hasAuthorship W2330761719A5077491183 @default.
• W2330761719 hasAuthorship W2330761719A5078749744 @default.
• W2330761719 hasAuthorship W2330761719A5083044979 @default.
• W2330761719 hasAuthorship W2330761719A5083956139 @default.
• W2330761719 hasAuthorship W2330761719A5087211317 @default.
• W2330761719 hasAuthorship W2330761719A5090063962 @default.
• W2330761719 hasBestOaLocation W23307617192 @default.
• W2330761719 hasConcept C120770815 @default.
• W2330761719 hasConcept C126322002 @default.
• W2330761719 hasConcept C142724271 @default.
• W2330761719 hasConcept C164705383 @default.
• W2330761719 hasConcept C180032290 @default.
• W2330761719 hasConcept C2776670291 @default.
• W2330761719 hasConcept C2779075594 @default.
• W2330761719 hasConcept C2779134260 @default.
• W2330761719 hasConcept C2779967694 @default.
• W2330761719 hasConcept C2780404050 @default.
• W2330761719 hasConcept C2781103887 @default.
• W2330761719 hasConcept C2781128415 @default.
• W2330761719 hasConcept C71924100 @default.
• W2330761719 hasConcept C90924648 @default.
• W2330761719 hasConceptScore W2330761719C120770815 @default.
• W2330761719 hasConceptScore W2330761719C126322002 @default.
• W2330761719 hasConceptScore W2330761719C142724271 @default.
• W2330761719 hasConceptScore W2330761719C164705383 @default.
• W2330761719 hasConceptScore W2330761719C180032290 @default.
• W2330761719 hasConceptScore W2330761719C2776670291 @default.
• W2330761719 hasConceptScore W2330761719C2779075594 @default.
• W2330761719 hasConceptScore W2330761719C2779134260 @default.
• W2330761719 hasConceptScore W2330761719C2779967694 @default.
• W2330761719 hasConceptScore W2330761719C2780404050 @default.
• W2330761719 hasConceptScore W2330761719C2781103887 @default.
• W2330761719 hasConceptScore W2330761719C2781128415 @default.
• W2330761719 hasConceptScore W2330761719C71924100 @default.
• W2330761719 hasConceptScore W2330761719C90924648 @default.
• W2330761719 hasIssue "Suppl 2" @default.
• W2330761719 hasLocation W23307617191 @default.
• W2330761719 hasLocation W23307617192 @default.
• W2330761719 hasOpenAccess W2330761719 @default.
• W2330761719 hasPrimaryLocation W23307617191 @default.
• W2330761719 hasRelatedWork W200009620 @default.

• next